Pharmaceutical companies are changing their business interests in Canada following new pricing regulations, according to a Pink Sheet report.
According to the report, Roche has withdrawn from consideration its anticancer treatment Tecentriq, which was under review by two health technology appraisal bodies.
To read the full report, click here. (Paid subscription required)
